BILR 355 BS

DRUG7 trials

Sponsors

Boehringer Ingelheim

Conditions

HIV InfectionsHealthy

Phase 1

Pharmacokinetic Interaction Between TRUVADA™ and BILR 355 BS Plus Ritonavir in Healthy Volunteers

CompletedNCT02253901

Boehringer IngelheimHealthy

Start: 2005-03-31Updated: 2014-10-01

A Safety, Tolerability and Preliminary Pharmacokinetics of BILR 355 BS Single-rising Dose Study in Healthy Male Volunteers

CompletedNCT02254538

Boehringer IngelheimHealthy

Start: 2002-05-31Updated: 2014-10-02

Study of Pharmacokinetic Interaction Between Kaletra® (LPV/r) and BILR 355 BS Plus Ritonavir in Healthy Subjects

CompletedNCT02256826

Boehringer IngelheimHealthy

Start: 2005-04-30Updated: 2014-10-06

Effect of Different Boosting Agents on Pharmacokinetics of BILR 355 BS Dissolved in Polyethylene Glycol 400 (PEG 400) in Healthy Male Volunteers

CompletedNCT02257008

Boehringer IngelheimHealthy

Start: 2003-03-31Updated: 2014-10-06

Study of Pharmacokinetic Interaction Between Combivir® (ZDV+3TC) and BILR 355 BS Plus Ritonavir in Healthy Subjects

CompletedNCT02256774

Boehringer IngelheimHealthy

Start: 2004-10-31Updated: 2014-10-06

Pharmacokinetic Interaction Between Tipranavir and BILR 355 BS Plus Ritonavir in Healthy Male Volunteers

CompletedNCT02257021

Boehringer IngelheimHealthy

Start: 2005-02-28Updated: 2014-10-06

Phase 2

Phase II Study on the Antiviral Activity and Safety of BILR 355 BS in HIV-1 Infected, NNRTI-treated Patients

TerminatedNCT00294372

Boehringer IngelheimHIV Infections

Start: 2006-02-28Target: 36Updated: 2013-11-14